TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?
Authors:
Open Access
- 1 November 2018
- journal article
- review article
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 11, 845-853
Abstract
Type 2 diabetes (DM2) constitutes 90%–95% of the diabetes cases and is increasing at an alarming rate in the world. The Centers for Disease Control and Prevention (CDC) estimates that more than 29 million people in the United States have diabetes, which often causes mortality from macrovascular complications and morbidity from microvascular complications. Despite these troubling facts, there is currently no widely accepted staging system for DM2 like there is for cancer. TNM oncologic staging has taken a complex condition like cancer and conveyed likelihood of survival in simple alpha-numeric terms that both patients and providers can understand. Oncology is now entering the era of precision medicine where cancer treatment is increasingly being tailored to each patient’s cancer. In contrast, DM2 lacks a staging system and remains a largely invisible disease even though it kills more Americans and costs more to treat than cancer. Is a comparable staging system for DM2 possible? We propose the Diabetes Staging System for DM2 that utilizes macrovascular events, microvascular complications, estimated glomerular filtration rate (GFR), and hemoglobin A1C to stage DM2.Keywords
This publication has 33 references indexed in Scilit:
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathNew England Journal of Medicine, 2011
- Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2010
- Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalencePopulation Health Metrics, 2010
- History of the FIGO cancer staging systemInternational Journal of Gynecology & Obstetrics, 2008
- UISESS scale for staging and classifying clinical–epidemiological risk in type 2 diabetes mellitus and for establishing multidiscipinary preventive actionsPreventive Medicine, 2005
- Duloxetine vs. placebo in patients with painful diabetic neuropathyPain, 2005
- Health-Related Quality of Life and Treatment Satisfaction in Dutch Patients With Type 2 DiabetesDiabetes Care, 2002
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed moodNeurology, 1987
- Photocoagulation Treatment of Proliferative Diabetic Retinopathy: The Second Report of Diabetic Retinopathy Study FindingsOphthalmology, 1978